{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:06:41Z","timestamp":1778706401742,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32-AR-007258"],"award-info":[{"award-number":["T32-AR-007258"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P60-AR-047785"],"award-info":[{"award-number":["P60-AR-047785"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1634-8","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T12:30:30Z","timestamp":1530793830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6935-880X","authenticated-orcid":false,"given":"April M.","family":"Jorge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald B.","family":"Melles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharan K.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen H.","family":"Costenbader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind","family":"Ramsey-Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Sam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Esdaile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann E.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. B.","family":"Urowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Askanase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Aranow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"issue":"4","key":"1634_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/0961203307086643","volume":"17","author":"G Ruiz-Irastorza","year":"2008","unstructured":"Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus. 2008;17(4):271\u20133.","journal-title":"Lupus"},{"issue":"2","key":"1634_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195\u2013205.","journal-title":"Ann Rheum Dis"},{"key":"1634_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJM199101173240303","volume":"324","author":"A Randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","year":"1991","unstructured":"A Randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian hydroxychloroquine study group. N Engl J Med. 1991;324:150\u20134.","journal-title":"N Engl J Med"},{"issue":"9","key":"1634_CR4","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarcon","year":"2007","unstructured":"Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, Reveille JD, Group LS. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168\u201372.","journal-title":"Ann Rheum Dis"},{"key":"1634_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","volume":"13","author":"M Petri","year":"2011","unstructured":"Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011;13:77\u201380.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"1634_CR6","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/art.22159","volume":"54","author":"ME Clowse","year":"2006","unstructured":"Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640\u20137.","journal-title":"Arthritis Rheum"},{"key":"1634_CR7","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1177\/0961203312450084","volume":"21","author":"E Cairoli","year":"2012","unstructured":"Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21:1178\u201382.","journal-title":"Lupus"},{"issue":"4","key":"1634_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1303006","volume":"369","author":"JR O'Dell","year":"2013","unstructured":"O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307\u201318.","journal-title":"N Engl J Med"},{"key":"1634_CR9","doi-asserted-by":"crossref","unstructured":"Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, Leatherman S, Mikuls TR, Anis AH. Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann Intern Med. 2017;167(1):8\u201316.","DOI":"10.7326\/M16-0713"},{"issue":"1","key":"1634_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1634_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12016-015-8469-8","volume":"49","author":"N Costedoat-Chalumeau","year":"2015","unstructured":"Costedoat-Chalumeau N, Dunogue B, Leroux G, Morel N, Jallouli M, Le Guern V, Piette JC, Brezin AP, Melles RB, Marmor MF. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. 2015;49(3):317\u201326.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1634_CR12","doi-asserted-by":"crossref","unstructured":"Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40(8):1482\u20136.","DOI":"10.1002\/art.1780400817"},{"issue":"7","key":"1634_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0161-6420(03)00409-3","volume":"110","author":"I Mavrikakis","year":"2003","unstructured":"Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110(7):1321\u20136.","journal-title":"Ophthalmology"},{"issue":"6","key":"1634_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/acr.20133","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(6):775\u201384.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"1634_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/rheumatology\/kev357","volume":"55","author":"HJ Ding","year":"2016","unstructured":"Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity. Rheumatology. 2016;55(6):957\u201367.","journal-title":"Rheumatology"},{"key":"1634_CR16","unstructured":"Bourke BJ, Jones S, Rajammal AK, Silman A, Smith R. Hydroxychloroquine and ocular toxicity recommendations on screening. The Royal College of Ophthalmologists in association with The British Society for Rheumatology and the British Association of Dermatologists. 2009."},{"issue":"2","key":"1634_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","volume":"118","author":"MF Marmor","year":"2011","unstructured":"Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415\u201322.","journal-title":"Ophthalmology"},{"issue":"12","key":"1634_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453\u201360.","journal-title":"JAMA Ophthalmol"},{"key":"1634_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajo.2016.06.045","volume":"170","author":"RB Melles","year":"2016","unstructured":"Melles RB, Marmor MF. The prevalence of hydroxychloroquine retinopathy and toxic dosing, and the role of the ophthalmologist in reducing both. Am J Ophthalmol. 2016;170:240.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1634_CR20","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. American Academy of O: recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386\u201394.","journal-title":"Ophthalmology"},{"key":"1634_CR21","doi-asserted-by":"crossref","unstructured":"Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. American Journal of Medicine. 1983;75:40\u20135.","DOI":"10.1016\/0002-9343(83)91269-X"},{"issue":"7","key":"1634_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0161-6420(03)00409-3","volume":"110","author":"I Mavrikakis","year":"2003","unstructured":"Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110(7):1321\u20136.","journal-title":"Ophthalmology"},{"issue":"2","key":"1634_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3928\/23258160-20170130-01","volume":"48","author":"MF Marmor","year":"2017","unstructured":"Marmor MF. Hydroxychloroquine screening alert: change is in the wind. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):96\u20138.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"7","key":"1634_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaophthalmol.2016.1252","volume":"134","author":"JE Kim","year":"2016","unstructured":"Kim JE, Marmor MF. Update on screening recommendations for hydroxychloroquine retinopathy. JAMA Ophthalmol. 2016;134(7):849.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1634_CR25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/bjd.15567","volume":"176","author":"WR Tucker","year":"2017","unstructured":"Tucker WR, Galloway J, Walsh S. The gathering storm: hydroxychloroquine retinopathy screening in the U.K. Br J Dermatol. 2017;176(6):1420\u20131.","journal-title":"Br J Dermatol"},{"key":"1634_CR26","doi-asserted-by":"publisher","unstructured":"Gonzalez-Suarez ML, Contreras G. Lower kidney allograft survival in African-Americans compared to Hispanic-Americans with lupus. Lupus. 2017; \n                    https:\/\/doi.org\/10.1177\/0961203317699287\n                    \n                  .","DOI":"10.1177\/0961203317699287"},{"issue":"7","key":"1634_CR27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0161-6420(02)01168-5","volume":"109","author":"MF Marmor","year":"2002","unstructured":"Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of ophthalmology. Opthamology. 2002;109(7):1377\u201382.","journal-title":"Opthamology"},{"issue":"4","key":"1634_CR28","first-page":"251","volume":"19","author":"BT Blak","year":"2011","unstructured":"Blak BT, et al. Generalisability of the health improvement network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251\u20135.","journal-title":"Inform Prim Care"},{"key":"1634_CR29","unstructured":"Plaquenil (hydroxychloroquine) [product mongraph]. Laval, Quebec, Canada: Sanofi-aventis Canada; 2018."},{"key":"1634_CR30","doi-asserted-by":"crossref","unstructured":"Devine B. Case number 25: gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650\u20135. FDB Solutions: Multilex. \n                    https:\/\/www.fdbhealth.co.uk\/solutions\/multilex\n                    \n                  . (Accessed date April 2017).","DOI":"10.1177\/106002807400801104"},{"issue":"5","key":"1634_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/EDE.0b013e31825fa218","volume":"23","author":"NH Rod","year":"2012","unstructured":"Rod NH, Lange T, Andersen I, Marott JL, Diderichsen F. Additive interaction in survival analysis: use of the additive hazards model. Epidemiology. 2012;23(5):733\u20137.","journal-title":"Epidemiology"},{"issue":"3","key":"1634_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3346\/jkms.2017.32.3.522","volume":"32","author":"DR Eo","year":"2017","unstructured":"Eo DR, Lee MG, Ham DI, Kang SW, Lee J, Cha HS, Koh E, Kim SJ. Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci. 2017;32(3):522\u20137.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"1634_CR33","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/j.1756-185X.2010.01478.x","volume":"13","author":"S Kobak","year":"2010","unstructured":"Kobak S, Deveci H. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis. 2010;13(3):e11\u20135.","journal-title":"Int J Rheum Dis"},{"key":"1634_CR34","unstructured":"Jorge A, Rai S, Choi HK. The risk of hydroxychloroquine toxic retinopathy and its risk factors in the treatment of rheumatic diseases: a systematic review [abstract]. Arthritis Rheum. 2017;69(Suppl 10)"},{"issue":"11","key":"1634_CR35","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3899\/jrheum.150379","volume":"42","author":"L Durcan","year":"2015","unstructured":"Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42(11):2092\u20137.","journal-title":"J Rheumatol"},{"key":"1634_CR36","unstructured":"Statistics on Obesity, Physical Activity and Diet- England, 2016. NHS Digital; 2016. \n                    http:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/statistics-on-obesity-physical-activity-and-diet\/statistics-on-obesity-physical-activity-and-diet-england-2016\n                    \n                  ."},{"issue":"10","key":"1634_CR37","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ophtha.2011.07.020","volume":"118","author":"MD Walvick","year":"2011","unstructured":"Walvick MD, Walvick MP, Tongson E, Ngo CH. Hydroxychloroquine: lean body weight dosing. Ophthalmology. 2011;118(10):2100. author reply 2101","journal-title":"Ophthalmology"},{"key":"1634_CR38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2147\/OPTH.S66531","volume":"8","author":"DJ Browning","year":"2014","unstructured":"Browning DJ, Lee C, Rotberg D. The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. Clin Ophthalmol. 2014;8:1401\u20137.","journal-title":"Clin Ophthalmol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1634-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1634-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1634-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:56:09Z","timestamp":1589550969000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1634-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1634-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,5]]},"assertion":[{"value":"20 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Partners Human Research Committee, protocol number 2017P000399. Informed consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AEC, UCB; MU, UCB; AA, Exagen; MP, Anthera Inc., Glaxo Smith Kline, EMD Serono, Eli Lilly and Company, Bristol Meyer Squibb, Amgen, United Rheumatology, Global Academy, Exagen, HKC, Selecta, Horizon, AstraZeneca. The other authors have declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"133"}}